[go: up one dir, main page]

WO2013016741A1 - Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement - Google Patents

Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement Download PDF

Info

Publication number
WO2013016741A1
WO2013016741A1 PCT/ZA2011/000053 ZA2011000053W WO2013016741A1 WO 2013016741 A1 WO2013016741 A1 WO 2013016741A1 ZA 2011000053 W ZA2011000053 W ZA 2011000053W WO 2013016741 A1 WO2013016741 A1 WO 2013016741A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
dietary supplement
berberine
weight loss
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ZA2011/000053
Other languages
English (en)
Inventor
Conrad Anton SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/ZA2011/000053 priority Critical patent/WO2013016741A1/fr
Publication of WO2013016741A1 publication Critical patent/WO2013016741A1/fr
Anticipated expiration legal-status Critical
Priority to ZA2014/01237A priority patent/ZA201401237B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • Insulin is an important controller of organic metabolism. It acts both directly and indirectly on most bodily tissues. Its actions can be divided into two broad categories:
  • the invention is based on the proposition that aspects of fat breakdown and use for providing energy are enhanced in the absence of insulin. This can occur normally between meals when secretion of insulin is minimal but the effect becomes extreme in diabetes mellitus when secretion of insulin is almost absent. When this happens, the aforementioned effects of insulin causing the production and storage of fat are reversed.
  • a dominant effect is that the enzyme hormone-sensitive lipase in the fat cells become strongly activated. This causes hydrolysis of stored triglycerides, releasing large quantities of fatty acids and glycerol from the adipose tissue into the circulating blood. The net effect or result is significant weight-loss.
  • a goal in this respect is a strategy in which the insulin level is lowered to a value which is still healthy but which does not promote fat deposition and fat storage, thereby counteracting insulin's obesity promoting effects.
  • the invention consists of a combination of naturally derived compounds and plant extracts that display complementary and synergistic pharmaceutical effects, all of which have been proven to be useful for the treatment or alleviation of insulin resistance.
  • the mode of action is via a triple-action mechanism, which optimises catabolic metabolism by lowering insulin levels and increasing the usage of fat for energy purposes, thereby assisting with weight loss.
  • the invention provides a dietary supplement which includes, in combination, berberine, banaba leaf and inositol.
  • LDLR low-density lipoprotein receptors
  • InsR insulin receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement, ledit complément alimentaire contenant de la berbérine, des feuilles de banaba et de l'inositol.
PCT/ZA2011/000053 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement Ceased WO2013016741A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000053 WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement
ZA2014/01237A ZA201401237B (en) 2011-07-22 2014-02-19 Dietary supplement for use in a weight loss program

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ZA2011/000053 WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Publications (1)

Publication Number Publication Date
WO2013016741A1 true WO2013016741A1 (fr) 2013-01-31

Family

ID=44543898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2011/000053 Ceased WO2013016741A1 (fr) 2011-07-22 2011-07-22 Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Country Status (2)

Country Link
WO (1) WO2013016741A1 (fr)
ZA (1) ZA201401237B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2923701A1 (fr) 2014-03-27 2015-09-30 Neopharmed Gentili S.r.l. Formulation pour le traitement et le contrôle du syndrome métabolique et des troubles corrélés
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012706A1 (fr) * 1991-01-23 1992-08-06 University Of Virginia Patents Foundation Procede permettant de reduire des taux eleves de glycemie chez l'homme
WO2002094018A1 (fr) * 2001-05-23 2002-11-28 Insmed Incorporated Compositions a base de d-chiro inositol et de composes hypolipidemiants et methodes therapeutiques les utilisant
WO2007090289A1 (fr) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinaisons d'extraits botaniques pour favoriser la santé cardio-vasculaire
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
WO2011061749A2 (fr) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents dérivés d'holoptelea integrifolia et leurs compositions destinées à lutter contre le syndrome métabolique et les maladies associées

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012706A1 (fr) * 1991-01-23 1992-08-06 University Of Virginia Patents Foundation Procede permettant de reduire des taux eleves de glycemie chez l'homme
WO2002094018A1 (fr) * 2001-05-23 2002-11-28 Insmed Incorporated Compositions a base de d-chiro inositol et de composes hypolipidemiants et methodes therapeutiques les utilisant
US7476406B1 (en) * 2004-05-17 2009-01-13 Nse Products, Inc. Multifaceted weight control system
WO2007090289A1 (fr) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinaisons d'extraits botaniques pour favoriser la santé cardio-vasculaire
EP2070926A1 (fr) * 2006-09-30 2009-06-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Dérivés de 13,13a-dihydroberbérine, leur composition pharmaceutique et leurs utilisations
US20080268039A1 (en) * 2007-03-06 2008-10-30 Soft Gel Technologies, Inc. Loquat compositions
WO2011061749A2 (fr) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents dérivés d'holoptelea integrifolia et leurs compositions destinées à lutter contre le syndrome métabolique et les maladies associées

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2923701A1 (fr) 2014-03-27 2015-09-30 Neopharmed Gentili S.r.l. Formulation pour le traitement et le contrôle du syndrome métabolique et des troubles corrélés
ITUA20163025A1 (it) * 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
WO2017187375A1 (fr) * 2016-04-29 2017-11-02 Sochim International S.P.A. Composition pour le traitement du syndrome des ovaires polykystiques
EP3448370B1 (fr) 2016-04-29 2020-10-21 Sochim International SpA Composition pour le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
ZA201401237B (en) 2015-08-26

Similar Documents

Publication Publication Date Title
Chantre et al. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity
AU2002364213B2 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
EP2440201A1 (fr) Procédés et compositions de traitement de résistance à l'insuline, du diabète sucré de type 2, du syndrome métabolique et de troubles associés
Hoffman et al. Thermogenic effect of an acute ingestion of a weight loss supplement
CN104366510A (zh) 茶叶茶氨酸保健食品组合物及其制备方法
HUE034393T2 (en) Increasing drug bioavailability in naltrexone therapy
AU2016322537B2 (en) Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
Joyal A perspective on the current strategies for the treatment of obesity
US8349373B1 (en) Dietary supplement for use in a weight loss program
BRPI0820455B1 (pt) Composição para agir sobre a síndrome metabólica
WO2013016741A1 (fr) Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement
US8420131B2 (en) Composition for obesity treatment
WO2004085462A2 (fr) Procede et composition pour faire baisser le taux de ghreline
US9278104B2 (en) Methods and materials for reducing multiple risk factors associated with the metabolic syndrome
WO2005041995A1 (fr) Inhibiteur de l'activite de l'alpha-glucosidase
JP2020535222A (ja) 満腹および／または食欲に関与するペプチドレベルの調節による体重管理のための組成物
JP6650053B2 (ja) ブチリデンフタリドの用途
CN102526198A (zh) 一种以肉桂和铬为添加剂的药品及保健品的制备方法
EP3860615B1 (fr) Composition orale comprenant de la b-escine et utilisation associée
CN102335362B (zh) 一种治疗2型糖尿病胰岛素抵抗的中药
WO2013016742A1 (fr) Composition utilisable dans le cadre d'un traitement contre l'obésité
BATUBARA et al. The potency of Berastagi sweet orange (Citrus sinensis) peel extract for obesity treatment: An experimental study in male rats
KR20100028616A (ko) 비만 개선용 경구 조성물
Górska et al. Apple Cider Vinegar in the Combat Against Type 2 Diabetes and Obesity–An Overview of Recent Research
CN106551942A (zh) 一种治疗代谢综合征的药物组合物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751783

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751783

Country of ref document: EP

Kind code of ref document: A1